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Review
Irritable bowel syndrome (IBS) is a clinical condition charac-
terized by abdominal pain, bloating, flatus, and altered bowel 
habits.1,2 Several studies conducted using barostat and similar 
devices indicate that these symptoms may be induced by lumi-
nal distension in association with visceral hypersensitivity. 
This suggests that dietary factors could modify intestinal 
luminal distension by increasing water and gas volume and 
thus may be suitable targets for therapy.1,2 The role of dietary 
components in inducing IBS symptoms is difficult to explore. 
Several studies have suggested a possible role for food allergy 
or food intolerance in IBS pathogenesis.1,3 Food allergy is 
defined as a reproducible adverse reaction arising from spe-
cific immune responses occurring on exposure to specific 
food antigens. Whenever similar reactions occur without evi-
dence of immunologic mechanisms, they are named “food 
intolerance.”3 The latter has been considered in IBS pathogen-
esis, but questionable outcomes have been obtained due to 
issues surrounding diagnostic tools and difficulties in con-
ducting well-designed dietary trials. In addition, accurate 
identification of the foods contributing to symptoms is diffi-
cult to achieve and fraught with complexity, given that meals 
are often complex mixtures of dietary components, and the 
timing of symptom onset can vary, both with different foods 
and with the same food in different patients.4–8 However, 
recent evidence has suggested that foods do not seem to be the 
cause of the condition, only the triggering factors of symptom 
onset.9 As aforesaid, identification of trigger foods could be 
extremely difficult, especially in the case of food intolerance.3 
Many published studies report specific food intolerance using 
patient questionnaires, although this is an unreliable method 
given the mix of foods included in meals and snacks and the 
likelihood of pinpointing the wrong culprit.10,11 At the same 
time, there is a consistent lack of clear evidence for “food 
allergy” in IBS and also on rechallenge with suspect trigger 
foods, which has not been successful in identifying reliable 
immunologic markers.12
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Abstract
Irritable bowel syndrome (IBS) is a condition characterized by abdominal pain, bloating, flatus, and altered bowel habits. The role of dietary 
components in inducing IBS symptoms is difficult to explore. To date, foods are not considered a cause but rather symptom-triggering 
factors. Particular interest has been given to the so-called FODMAPs (fermentable oligo-, di-, and monosaccharides and polyols). We 
aimed to summarize the evidence from the most common approaches to manage suspected food intolerance in IBS, with a particular 
interest in the role of FODMAPs and the effects of a low FODMAP diet. We reviewed literature, consulting PubMed and Medline 
by using the search terms FODMAP(s), fructose, lactose, fructans, galactans, polyols (sorbitol, mannitol, maltitol, xylitol, erythritol, 
polydextrose, and isomalt), irritable bowel syndrome, and functional gastrointestinal symptoms. FODMAP-restricted diets have been 
used for a long time to manage patients with IBS. The innovation in the so-called FODMAP concept is that a global restriction should 
have a more consistent effect than a limited one in preventing abdominal distension. Even though all the potential low FODMAP diets 
provide good relief of symptoms in many patients, there is just a little relief in others. Several studies highlight the role of low FODMAP 
diets to improve symptoms in patients with IBS. The evidence on this dietary approach supports the hypothesis that a low FODMAP diet 
should be the first dietary approach. However, many points remain to be clarified, including the evaluation of possibly significant nutrition 
concerns. (Nutr Clin Pract.XXXX;xx:xx-xx)
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In recent decades, the role of dietary components has been 
better explored and highlighted. Some studies report that cer-
tain food components can contribute to symptom onset due to 
malabsorption of carbohydrates9,13 and stimulate hypersensi-
tivity through food chemical ingestion.11 Moreover, a new 
clinical condition—nonceliac gluten sensitivity (NCGS)—
entered this complex situation, and it has been suggested that it 
may be important in causing IBS in a subgroup of patients,14–16 
although contradictory data seem to deny a role for the gluten-
free diet in the treatment of these IBS-like patients.17 More 
recently, international literature has paid specific attention to 
the so-called FODMAPs (fermentable oligo-, di-, and mono-
saccharides and polyols; ie, fructose, lactose, fructans, galac-
tans, and polyols). They form a heterogeneous group of poorly 
absorbed, short-chain carbohydrates, which seem to be possi-
ble IBS symptom inducers and whose restriction from the diet 
could produce beneficial effects in patients with IBS.9,18–56
Therefore, the aim of our article is to summarize the latest 
evidence and applications of the most common research 
approaches to manage suspected food intolerance in IBS. 
Particular interest will be paid to the role of FODMAPs and to 
the effects of a low FODMAP diet in patients with IBS.
Methods
This review is based on a PubMed and Medline search, con-
ducted in November 2014, for all available articles with the 
search terms, alone and matched to each other: FODMAP(s), 
fructose, lactose, fructans, galactans, polyols (sorbitol, man-
nitol, maltitol, xylitol, erythritol, polydextrose, and isomalt), 
irritable bowel syndrome, and functional gastrointestinal 
symptoms. The references of identified eligible articles were 
also searched for further studies. The search provided 391 eli-
gible studies, of which the abstract and, whenever possible, full 
text were read and analyzed. Considering the specific interest 
of our research, to provide a practical point of view to evaluate, 
diagnose, and manage possible FODMAP intolerance in IBS 
and patients with functional gastrointestinal (GI) symptoms, 
we excluded papers not written in English, letters to the editor, 
case reports, studies that are too small (<5 patients studied), 
exclusive biochemical and experimental research, reviews 
reporting data about the same original studies, and research 
otherwise not of our specific interest (ie, matching error). We 
considered 40 articles: 31 original studies and 9 reviews 
(Figure 1 and Tables 1 and 2).9,18–56
What Are FODMAPs, and How Much Is 
Too Much?
During the past several decades, and probably in conjunction 
with urbanization, reports conflict about whether sugar intake 
has increased.57 Nonetheless, several studies performed in the 
United States agree on the same point: the proportion of sugar 
intake made up of fructose is increasing.58 The even greater 
consumption of fruit juice, as well as the use of high-fructose 
corn syrup (which contains 42%–55% fructose) as sweeteners 
in many manufactured foods, seems to play the leading role. In 
the past 4 decades, the proportion of energy from high-calorie 
sweeteners has increased to about 22% of the total daily calorie 
intake, of which more than 80% can be attributed to increased 
consumption of soft drinks and/or sugared fruit drinks.57–62 To 
date, there are no direct studies of time trends in fructan inges-
tion, but indirect evidence indicates changes in their consump-
tion patterns.60 The intake of major sources of fructans, such as 
pasta and pizza, has increased, and at the same time the type of 
fructan in the diet is changing.61–63 The widespread use of fruc-
tans is attributable both to the unique technological benefits in 
food manufacture (they improve palatability and stability of 
foods) and to the putative nutrition benefits as “functional 
foods.”61 There are no data available on polyol intake trends, 
but it is likely that their use as food additives has increased 
with the desire to produce “sugar-free” products to lower 
energy intake and to protect dentition.57,58,62–65
Throughout the 1980s and 1990s, evidence (especially 
observational cohort studies) of a possible induction of func-
tional bowel disorders and IBS symptoms due to the poorly 
absorbed, short-chain carbohydrates and polyols (lactose, fruc-
tose, and sorbitol) has confirmed that dietary restriction of all 
three together could cause symptomatic relief.* More recent 
studies confirmed the above-mentioned results.† However, it is 
clear that these sugars are not the only answer. A deeper exami-
nation of the international literature on the biochemistry and 
physiology of digestion of other carbohydrates suggests 
Figure 1. Method of research and selection of papers suitable 
for the review. FODMAPs, fermentable oligo-, di-, and 
monosaccharides and polyols.
*References 18, 25, 27, 31, 36, 38, 39, 41, 43, 49.
†References 19–22, 29, 30, 33, 34, 40, 44, 45, 51.
 by guest on March 24, 2015ncp.sagepub.comDownloaded from 
3T
ab
le
 1
. 
O
ri
gi
na
l R
es
ea
rc
h 
S
el
ec
te
d 
fo
r 
R
ev
ie
w
, i
n 
C
hr
on
ol
og
ic
al
 O
rd
er
.
A
ut
ho
rs
Y
ea
r 
of
 
P
ub
li
ca
ti
on
T
yp
e 
of
 
P
ub
li
ca
ti
on
D
es
ig
n 
of
 th
e 
S
tu
dy
N
o.
 o
f 
P
at
ie
nt
s 
an
d 
C
on
tr
ol
s
G
I 
D
is
or
de
r
R
es
ul
ts
A
nd
er
ss
on
 a
nd
 
N
yg
re
n1
8
19
78
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
4 
pa
ti
en
ts
, 4
 c
on
tr
ol
s
D
ia
rr
he
a 
an
d 
co
li
c 
pa
in
s
P
at
ie
nt
s 
un
de
r 
fr
uc
to
se
-f
re
e 
di
et
 m
ig
ht
 h
av
e 
pa
rt
ia
l f
ru
ct
os
e 
m
al
ab
so
rp
ti
on
.
R
av
ic
h 
et
 a
l4
1
19
83
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
16
 h
ea
lt
hy
 
pa
rt
ic
ip
an
ts
N
on
e
In
co
m
pl
et
e 
ab
so
rp
ti
on
 o
f 
fr
uc
to
se
 s
ho
ul
d 
be
 c
on
si
de
re
d 
a 
po
ss
ib
le
 c
as
e 
of
 G
I 
sy
m
pt
om
s.
S
to
ne
-D
or
sh
ow
 
an
d 
L
ev
it
t4
8
19
87
O
ri
gi
na
l r
es
ea
rc
h
R
an
do
m
iz
ed
 
co
nt
ro
ll
ed
 tr
ia
l
15
 h
ea
lt
hy
 
pa
rt
ic
ip
an
ts
 (
10
 
in
te
rv
en
ti
on
 g
ro
up
, 
5 
co
nt
ro
ls
)
N
on
e
A
da
pt
at
io
n 
of
 c
ol
on
ic
 b
ac
te
ri
a 
to
 c
ar
bo
hy
dr
at
e 
m
al
ab
so
rp
ti
on
 is
 v
ar
ia
bl
e 
an
d 
m
ay
 d
ep
en
d 
on
 q
ua
nt
it
y 
or
 
na
tu
re
 o
f 
th
e 
ca
rb
oh
yd
ra
te
.
R
um
es
se
n 
an
d 
G
ud
m
an
d-
H
oy
er
43
19
88
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
25
 p
at
ie
nt
s
F
un
ct
io
na
l 
bo
w
el
 d
is
ea
se
G
I 
di
st
re
ss
 m
ay
 b
e 
pr
ov
ok
ed
 b
y 
m
al
ab
so
rp
ti
on
 o
f 
sm
al
l 
am
ou
nt
s 
of
 f
ru
ct
os
e,
 s
or
bi
to
l, 
an
d 
fr
uc
to
se
-s
or
bi
to
l 
m
ix
tu
re
s 
in
 p
at
ie
nt
s 
w
it
h 
fu
nc
ti
on
al
 b
ow
el
 d
is
ea
se
.
S
ym
on
s 
et
 a
l4
9
19
92
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
15
 p
at
ie
nt
s,
 2
4 
he
al
th
y 
co
nt
ro
ls
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
IB
S
 s
ym
pt
om
s 
in
cr
ea
se
d 
in
 p
ar
al
le
l w
it
h 
in
cr
ea
si
ng
 d
os
e.
 
N
o 
si
gn
if
ic
an
t c
or
re
la
ti
on
 w
as
 o
bs
er
ve
d 
be
tw
ee
n 
th
e 
in
cr
ea
se
 in
 s
ym
pt
om
 s
co
re
 a
nd
 th
e 
in
cr
ea
se
 in
 p
ea
k 
hy
dr
og
en
 c
on
ce
nt
ra
ti
on
.
G
öt
ze
 a
nd
 M
ah
di
31
19
92
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
29
3 
pa
ti
en
ts
R
ec
ur
re
nt
 
ab
do
m
in
al
 
pa
in
, 
m
et
eo
ri
sm
, o
r 
di
ar
rh
ea
F
ru
ct
os
e 
m
al
ab
so
rp
ti
on
 m
ay
 b
e 
th
e 
ca
us
e 
of
 f
un
ct
io
na
l g
ut
 
di
so
rd
er
s.
F
er
ná
nd
ez
-B
añ
ar
es
 
et
 a
l2
7
19
93
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
25
 p
at
ie
nt
s,
 1
2 
he
al
th
y 
co
nt
ro
ls
IB
S
-l
ik
e 
sy
m
pt
om
s
S
ug
ar
 m
al
ab
so
rp
ti
on
 m
ay
 b
e 
im
pl
ic
at
ed
 in
 th
e 
de
ve
lo
pm
en
t 
of
 a
bd
om
in
al
 d
is
tr
es
s 
in
 a
 s
ub
se
t o
f 
pa
ti
en
ts
 w
it
h 
fu
nc
ti
on
al
 b
ow
el
 d
is
ea
se
.
M
is
hk
in
 e
t a
l3
6
19
97
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
52
0 
pa
ti
en
ts
F
un
ct
io
na
l 
dy
sp
ep
si
a
M
ul
ti
pl
e 
su
ga
r 
m
al
ab
so
rp
ti
on
 is
 c
om
m
on
 w
he
n 
la
ct
os
e 
m
al
di
ge
st
io
n/
m
al
ab
so
rp
ti
on
 is
 p
re
se
nt
.
C
la
us
en
 e
t a
l2
3
19
98
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
12
 h
ea
lt
hy
 
pa
rt
ic
ip
an
ts
N
on
e
F
ec
al
 v
ol
um
e 
in
 c
ar
bo
hy
dr
at
e-
in
du
ce
d 
di
ar
rh
ea
 is
 
pr
op
or
ti
on
al
 to
 th
e 
os
m
ot
ic
 f
or
ce
 o
f 
th
e 
m
al
ab
so
rb
ed
 
sa
cc
ha
ri
de
.
E
va
ns
 e
t a
l2
5
19
98
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
15
 p
at
ie
nt
s
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
C
ar
bo
hy
dr
at
e 
m
al
ab
so
rp
ti
on
 c
an
 p
ro
vo
ke
 s
ym
pt
om
s 
in
 
pa
ti
en
ts
 w
it
h 
IB
S
; n
o 
as
so
ci
at
io
n 
ca
n 
be
 p
ro
ve
d 
be
tw
ee
n 
su
ch
 a
 p
he
no
m
en
on
 a
nd
 je
ju
na
l h
yp
er
se
ns
it
iv
it
y 
or
 
dy
sm
ot
il
it
y.
R
um
es
se
n 
an
d 
G
ud
m
an
d-
H
oy
er
42
19
98
O
ri
gi
na
l r
es
ea
rc
h
S
in
gl
e-
bl
in
d,
 
cr
os
so
ve
r 
ra
nd
om
iz
ed
 
tr
ia
l
16
 h
ea
lt
hy
 
pa
rt
ic
ip
an
ts
N
on
e
G
I 
sy
m
pt
om
s 
af
te
r 
fr
uc
ta
ns
 in
cr
ea
se
d 
w
it
h 
in
cr
ea
si
ng
 d
os
e 
an
d 
de
cr
ea
si
ng
 c
ha
in
 le
ng
th
. T
he
 o
ve
ra
ll
 G
I 
ef
fe
ct
s 
of
 
sh
or
t-
ch
ai
n 
fr
uc
ta
ns
 s
ee
m
 s
im
il
ar
 to
 th
os
e 
of
 la
ct
ul
os
e.
L
ed
oc
ho
w
sk
i  
et
 a
l3
4
20
00
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
53
 f
ru
ct
os
e 
m
al
ab
so
rb
er
s
M
et
eo
ri
sm
 a
nd
/
or
 d
ia
rr
he
a
F
ru
ct
os
e-
 a
nd
 s
or
bi
to
l-
re
du
ce
d 
di
et
s 
re
du
ce
d 
G
I 
sy
m
pt
om
s 
an
d 
im
pr
ov
ed
 m
oo
d 
an
d 
ea
rl
y 
si
gn
s 
of
 d
ep
re
ss
io
n. (c
on
ti
nu
ed
)
 by guest on March 24, 2015ncp.sagepub.comDownloaded from 
4 
A
ut
ho
rs
Y
ea
r 
of
 
P
ub
li
ca
ti
on
T
yp
e 
of
 
P
ub
li
ca
ti
on
D
es
ig
n 
of
 th
e 
S
tu
dy
N
o.
 o
f 
P
at
ie
nt
s 
an
d 
C
on
tr
ol
s
G
I 
D
is
or
de
r
R
es
ul
ts
G
ol
ds
te
in
 e
t a
l3
0
20
00
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
94
 p
at
ie
nt
s 
w
it
h 
IB
S
, 1
45
 p
at
ie
nt
s 
w
it
h 
fu
nc
ti
on
al
 g
ut
 
di
so
rd
er
IB
S
 a
nd
 I
B
S
-l
ik
e 
sy
m
pt
om
s 
no
t 
fu
lf
il
li
ng
 R
om
e 
II
 c
ri
te
ri
a
C
om
bi
ne
d 
su
ga
r 
m
al
ab
so
rp
ti
on
 is
 c
om
m
on
 in
 f
un
ct
io
na
l 
bo
w
el
 d
is
or
de
rs
. D
ie
ta
ry
 r
es
tr
ic
ti
on
 s
ho
ul
d 
be
 
im
pl
em
en
te
d 
be
fo
re
 in
st
it
ut
io
n 
of
 d
ru
g 
th
er
ap
y.
R
an
a 
et
 a
l4
0
20
01
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
25
 p
at
ie
nt
s,
 2
5 
he
al
th
y 
co
nt
ro
ls
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
P
at
ie
nt
s 
w
it
h 
di
ar
rh
ea
l t
yp
e 
of
 I
B
S
 h
av
e 
a 
hi
gh
er
 in
ci
de
nc
e 
of
 la
ct
os
e 
in
to
le
ra
nc
e 
co
m
pa
re
d 
w
it
h 
sp
as
ti
c 
an
d 
m
ix
ed
 
IB
S
.
C
ho
i e
t a
l2
1
20
03
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
18
3 
pa
ti
en
ts
IB
S
-l
ik
e 
sy
m
pt
om
s
F
ru
ct
os
e 
in
to
le
ra
nc
e 
m
ay
 c
au
se
 u
ne
xp
la
in
ed
 G
I 
sy
m
pt
om
s.
B
ey
er
 e
t a
l2
0
20
05
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
15
 h
ea
lt
hy
 
pa
rt
ic
ip
an
ts
N
on
e
F
ru
ct
os
e,
 in
 a
m
ou
nt
s 
co
m
m
on
ly
 c
on
su
m
ed
, m
ay
 r
es
ul
t i
n 
m
il
d 
G
I 
di
st
re
ss
 in
 h
ea
lt
hy
 p
eo
pl
e.
F
er
ná
nd
ez
-B
añ
ar
es
 
et
 a
l2
8
20
06
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
36
 p
at
ie
nt
s
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
A
 m
al
ab
so
rb
ed
 s
ug
ar
-f
re
e 
di
et
 m
ig
ht
 b
e 
a 
lo
ng
-t
er
m
 
ef
fe
ct
iv
e 
th
er
ap
y 
in
 p
at
ie
nt
s 
w
it
h 
IB
S
.
S
he
ph
er
d 
an
d 
G
ib
so
n4
4
20
06
O
ri
gi
na
l r
es
ea
rc
h
R
et
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
62
 p
at
ie
nt
s
IB
S
-l
ik
e 
pa
ti
en
ts
C
om
pr
eh
en
si
ve
 f
ru
ct
os
e 
m
al
ab
so
rp
ti
on
 d
ie
ta
ry
 th
er
ap
y 
ac
hi
ev
es
 a
 h
ig
h 
le
ve
l o
f 
su
st
ai
ne
d 
ad
he
re
nc
e 
an
d 
go
od
 
sy
m
pt
om
at
ic
 r
es
po
ns
e.
S
he
ph
er
d 
et
 a
l9
20
08
O
ri
gi
na
l r
es
ea
rc
h
D
ou
bl
e-
bl
in
de
d,
 
ra
nd
om
iz
ed
, 
qu
ad
ru
pl
e 
ar
m
, p
la
ce
bo
-
co
nt
ro
ll
ed
 
ch
al
le
ng
e
25
 p
at
ie
nt
s
IB
S
-l
ik
e 
sy
m
pt
om
s
D
ie
ta
ry
 r
es
tr
ic
ti
on
 o
f 
fr
uc
to
se
 a
nd
/o
r 
fr
uc
ta
ns
 is
 li
ke
ly
 to
 b
e 
re
sp
on
si
bl
e 
fo
r 
sy
m
pt
om
at
ic
 im
pr
ov
em
en
t.
C
ho
i e
t a
l2
2
20
08
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
80
 p
at
ie
nt
s
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
IB
S
 s
ym
pt
om
s 
im
pr
ov
es
 o
n 
fr
uc
to
se
-r
es
tr
ic
te
d 
di
et
 d
es
pi
te
 
m
od
er
at
e 
im
pa
ct
 o
n 
li
fe
st
yl
e.
S
ko
og
 e
t a
l4
5
20
08
O
ri
gi
na
l r
es
ea
rc
h
D
ou
bl
e-
bl
in
d,
 
ra
nd
om
iz
ed
, 
cr
os
so
ve
r 
st
ud
y
30
 p
at
ie
nt
s,
 2
0 
he
al
th
y 
co
nt
ro
ls
IB
S
-l
ik
e 
pa
ti
en
ts
P
re
va
le
nc
e 
of
 f
ru
ct
os
e 
in
to
le
ra
nc
e 
is
 n
ot
 s
ig
ni
fi
ca
nt
ly
 
di
ff
er
en
t i
n 
he
al
th
 a
nd
 I
B
S
. C
ur
re
nt
 m
et
ho
ds
 f
or
 
id
en
ti
fy
in
g 
fr
uc
to
se
 in
to
le
ra
nc
e 
sh
ou
ld
 b
e 
m
od
if
ie
d 
to
 
m
or
e 
cl
os
el
y 
re
pr
od
uc
e 
fr
uc
to
se
 in
ge
st
io
n 
in
 d
ai
ly
 li
fe
.
B
ar
re
tt
 e
t a
l1
9
20
09
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
C
ro
hn
’s
 d
is
ea
se
 (
n 
=
 9
1)
, u
lc
er
at
iv
e 
co
li
ti
s 
(n
 =
 5
6)
, 
fu
nc
ti
on
al
 G
I 
di
so
rd
er
s 
(n
 =
 2
01
),
 
ce
li
ac
 d
is
ea
se
 (
n 
=
 1
36
),
 h
ea
lt
hy
 
vo
lu
nt
ee
rs
 (
n 
=
 7
1)
V
ar
io
us
, 
ac
co
rd
in
g 
to
 
th
e 
sp
ec
if
ic
 
di
se
as
e
C
ar
bo
hy
dr
at
e 
m
al
ab
so
rp
ti
on
 a
nd
 e
ar
ly
 r
is
e 
in
 b
re
at
h 
hy
dr
og
en
 a
ft
er
 la
ct
ul
os
e 
ar
e 
no
rm
al
 p
hy
si
ol
og
ic
 
ph
en
om
en
a.
(c
on
ti
nu
ed
)
T
ab
le
 1
. 
(c
on
ti
nu
ed
)
 by guest on March 24, 2015ncp.sagepub.comDownloaded from 
5A
ut
ho
rs
Y
ea
r 
of
 
P
ub
li
ca
ti
on
T
yp
e 
of
 
P
ub
li
ca
ti
on
D
es
ig
n 
of
 th
e 
S
tu
dy
N
o.
 o
f 
P
at
ie
nt
s 
an
d 
C
on
tr
ol
s
G
I 
D
is
or
de
r
R
es
ul
ts
O
ng
 e
t a
l3
7
20
10
O
ri
gi
na
l r
es
ea
rc
h
S
in
gl
e-
bl
in
d,
 
cr
os
so
ve
r 
in
te
rv
en
ti
on
 
tr
ia
l
15
 p
at
ie
nt
s,
 1
5 
he
al
th
y 
co
nt
ro
ls
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
F
O
D
M
A
P
s 
in
du
ce
 h
yd
ro
ge
n 
pr
od
uc
ti
on
 in
 th
e 
in
te
st
in
e 
an
d 
in
du
ce
 G
I 
an
d 
sy
st
em
ic
 s
ym
pt
om
s 
in
 p
at
ie
nt
s 
w
it
h 
IB
S
.
Z
ha
o 
et
 a
l5
1
20
10
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
31
 p
at
ie
nt
s,
 3
2 
he
al
th
y 
co
nt
ro
ls
IB
S
 (
R
om
e 
II
I 
cr
it
er
ia
)
S
IB
O
 in
cr
ea
se
s 
th
e 
li
ke
li
ho
od
 o
f 
la
ct
os
e 
in
to
le
ra
nc
e 
in
 
pa
ti
en
ts
 w
it
h 
IB
S
 a
s 
a 
di
re
ct
 r
es
ul
t o
f 
la
ct
os
e 
fe
rm
en
ta
ti
on
 
in
 th
e 
sm
al
l i
nt
es
ti
ne
, i
nd
ep
en
de
nt
 o
f 
or
oc
ec
al
 tr
an
si
t t
im
e 
an
d 
vi
sc
er
al
 s
en
si
ti
vi
ty
.
S
ta
ud
ac
he
r 
et
 a
l4
7
20
11
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
82
 p
at
ie
nt
s 
(3
9 
st
an
da
rd
 d
ie
t, 
43
 
lo
w
 F
O
D
M
A
P
 d
ie
t)
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
A
 lo
w
 F
O
D
M
A
P
 d
ie
t i
s 
m
or
e 
ef
fe
ct
iv
e 
th
an
 s
ta
nd
ar
d 
di
et
ar
y 
ad
vi
ce
 f
or
 I
B
S
 s
ym
pt
om
 c
on
tr
ol
.
S
ta
ud
ac
he
r 
et
 a
l4
6
20
12
O
ri
gi
na
l r
es
ea
rc
h
R
an
do
m
iz
ed
 
co
nt
ro
ll
ed
 tr
ia
l
41
 p
at
ie
nt
s 
(1
9 
in
 
in
te
rv
en
ti
on
 g
ro
up
, 
22
 in
 c
on
tr
ol
 g
ro
up
)
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
F
O
D
M
A
P
-r
es
tr
ic
te
d 
di
et
 w
as
 e
ff
ec
ti
ve
 in
 m
an
ag
in
g 
IB
S
 
sy
m
pt
om
s.
 A
 r
ed
uc
ti
on
 in
 c
on
ce
nt
ra
ti
on
 a
nd
 p
ro
po
rt
io
n 
of
 
lu
m
in
al
 b
if
id
ob
ac
te
ri
a 
af
te
r 
a 
4-
w
ee
k 
di
et
 w
as
 f
ou
nd
.
D
e 
R
oe
st
 e
t a
l2
4
20
13
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
90
 p
at
ie
nt
s
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
L
ow
 F
O
D
M
A
P
 d
ie
t s
ho
w
s 
ef
fi
ca
cy
 f
or
 p
at
ie
nt
s 
w
it
h 
IB
S
 in
 
co
nt
ro
ll
in
g 
sy
m
pt
om
s.
Y
ao
 e
t a
l5
0
20
14
O
ri
gi
na
l r
es
ea
rc
h
D
ou
bl
e-
bl
in
de
d,
 
pl
ac
eb
o-
co
nt
ro
ll
ed
 tr
ia
l
20
 p
at
ie
nt
s,
 2
1 
he
al
th
y 
co
nt
ro
ls
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
P
ol
yo
ls
 in
du
ce
 G
I 
sy
m
pt
om
s 
in
 p
at
ie
nt
s 
w
it
h 
IB
S
 
in
de
pe
nd
en
tl
y 
of
 th
ei
r 
ab
so
rp
ti
ve
 p
at
te
rn
s,
 s
ug
ge
st
in
g 
th
at
 
th
e 
di
et
ar
y 
re
st
ri
ct
io
n 
of
 p
ol
yo
ls
 m
ay
 b
e 
ef
fi
ca
ci
ou
s.
H
al
m
os
 e
t a
l3
2
20
14
O
ri
gi
na
l r
es
ea
rc
h
D
ou
bl
e-
bl
in
de
d,
 
ra
nd
om
iz
ed
, 
cr
os
so
ve
r,
 
pl
ac
eb
o-
co
nt
ro
ll
ed
 
ch
al
le
ng
e
30
 p
at
ie
nt
s,
 8
 h
ea
lt
hy
 
co
nt
ro
ls
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
D
ie
t l
ow
 in
 F
O
D
M
A
P
s 
ef
fe
ct
iv
el
y 
re
du
ce
d 
fu
nc
ti
on
al
 G
I 
sy
m
pt
om
s.
H
al
m
os
 e
t a
l5
4
20
14
O
ri
gi
na
l r
es
ea
rc
h
R
an
do
m
iz
ed
 
co
nt
ro
ll
ed
 tr
ia
l
27
 p
at
ie
nt
s,
 6
 h
ea
lt
hy
 
pa
rt
ic
ip
an
ts
IB
S
 (
R
om
e 
II
 
cr
it
er
ia
)
A
 lo
w
 F
O
D
M
A
P
 d
ie
t h
as
 a
 m
ar
ke
d 
ef
fe
ct
 o
n 
gu
t m
ic
ro
bi
ot
a 
co
m
po
si
ti
on
 c
om
pa
re
d 
w
it
h 
a 
ty
pi
ca
l A
us
tr
al
ia
n 
di
et
, 
re
du
ci
ng
 to
ta
l b
ac
te
ri
al
 a
bu
nd
an
ce
 a
nd
 in
cr
ea
si
ng
 f
ec
al
 
pH
.
P
ed
er
se
n 
et
 a
l5
3
20
14
O
ri
gi
na
l r
es
ea
rc
h
P
ro
sp
ec
ti
ve
 
ob
se
rv
at
io
na
l 
st
ud
y
19
 p
at
ie
nt
s
IB
S
 (
R
om
e 
II
I 
cr
it
er
ia
)
Q
ua
li
ty
 o
f 
li
fe
 in
 p
at
ie
nt
s 
w
it
h 
IB
S
 s
ig
ni
fi
ca
nt
ly
 im
pr
ov
ed
 
du
ri
ng
 lo
w
 F
O
D
M
A
P
 d
ie
ts
.
F
O
D
M
A
P
s,
 f
er
m
en
ta
bl
e 
ol
ig
o-
, d
i-
, a
nd
 m
on
os
ac
ch
ar
id
es
 a
nd
 p
ol
yo
ls
; G
I,
 g
as
tr
oi
nt
es
ti
na
l;
 I
B
S
, i
rr
it
ab
le
 b
ow
el
 s
yn
dr
om
e;
 S
IB
O
, s
m
al
l i
nt
es
ti
na
l b
ac
te
ri
al
 o
ve
rg
ro
w
th
.
T
ab
le
 1
. 
(c
on
ti
nu
ed
)
 by guest on March 24, 2015ncp.sagepub.comDownloaded from 
6 Nutrition in Clinical Practice XX(X)
involvement of fructo-oligosaccharides (fructans or FOS) and 
galacto-oligosaccharides (galactans or GOS); they are also 
short-chain carbohydrates and are incompletely absorbed in 
the human GI tract.23,26,37,42,47,48 Other potential culprits seem 
to be incompletely absorbed polyols (ie, mannitol, maltitol, 
and xylitol), used as artificial sweeteners, but also found natu-
rally in foods.50 Grouping these poorly absorbed, short-chain 
carbohydrates according to their chain length resulted in the 
acronym FODMAP.66–70
Historically, this term was specifically coined, in 2005, by a 
group of Australian researchers who theorized that foods con-
taining these forms of carbohydrates worsen the symptoms of 
some digestive disorders, such as IBS and inflammatory bowel 
disease (IBD).71 These short-chain highly osmotic carbohy-
drates are poorly absorbed in the small intestine and are rapidly 
fermented by bacteria in the gut, causing increased gas produc-
tion, bowel distension, bloating, cramping, and diarrhea—all 
symptoms of IBS, triggered in association with intrinsic vis-
ceral hypersensitivity.72
More specifically, free fructose is a simple sugar requiring 
no digestion, which can arrive in the intestinal lumen either as a 
free hexose in foods or following enzyme-mediated hydrolysis 
of sucrose or saccharose, a disaccharide composed of the mono-
saccharides fructose and glucose.73 It is absorbed by the small 
intestinal epithelium via 2 mechanisms: (1) in cotransport with 
glucose (GLUT-2) and, when in equimolar amounts with glu-
cose, fructose is taken up efficiently (eg, following sucrose 
hydrolysis), due to the insertion of GLUT-2 (a glucose/fructose-
specific transporter) into the apical membrane of the entero-
cyte73 and (2) by a specific alternative transporter (GLUT-5): in 
the case of excess relative to glucose, free fructose is taken up 
by GLUT-5, which is present on the apical border of entero-
cytes throughout the small intestine. Since the concentration of 
fructose is higher in the lumen than in the intestinal epithelial 
cells, a concentration gradient allows the fructose to flow down 
into the latter, assisted by transport proteins, but this mechanism 
is low capacity (ie, saturation at low levels).73 If the free fruc-
tose load is sufficiently large, its malabsorption is universal. 
However, about 40% of the general population exhibit very lim-
ited ability to absorb free fructose and are considered to have 
“fructose malabsorption.”73,74 Apples, cherries, mangoes, pears, 
watermelon (among fruits), asparagus, artichokes, sugar snap 
peas (among vegetables), honey, and high-fructose corn syrup 
are the most common foods containing fructose.73,74
Lactose is a disaccharide, made up of 2 sugar units (glucose 
and galactose), naturally occurring in mammalian milk, includ-
ing cows, sheep, and goats. Whenever an individual has an 
insufficient level of lactase (a condition that can be found in 
15%–100% of populations), the enzyme needed to hydrolyze 
the disaccharide to its constituent monosaccharides and whose 
levels can be influenced by factors such as genetics, ethnicity 
(Asian, African American, Hispanic, Native American, Alaska 
Native, and Pacific Islander), and other gut disorders, lactose 
behaves as a FODMAP.75 Nevertheless, this is a concentration-
dependent process, since it has been demonstrated that symp-
toms only occur in lactose malabsorbers when lactose is 
ingested in quantities in excess of 7 g, since most people have 
Table 2. Published Reviews Selected for Evaluation, in 
Chronological Order.
Authors
Year of 
Publication Results
Gibson 
et al29
2007 Restricting dietary intake 
of free fructose and/or 
fructans may have durable 
symptomatic benefits in 
patients with IBS.
Gibson38 2011 Dietary restriction of 
FODMAPs is an effective 
therapy in most patients with 
functional bowel symptoms 
and should be first-line 
therapy.
Magge and 
Lembo33
2012 The reduction of FODMAPs in 
a patient’s diet may improve 
functional GI symptoms.
McKenzie 
et al35
2012 FODMAP elimination diet 
seems to improve GI 
symptoms in patients with 
IBS, but there is a lack of 
high-grade evidence.
Putkonen 
et al39
2013 FODMAP restriction is 
efficacious for functional GI 
symptoms, but potentially 
negative effects on microbiota 
deserve attention.
Fedewa and 
Rao26
2014 Current research shows that 
the FODMAP diet may be 
effective in treating some 
patients with IBS.
Staudacher 
et al55
2014 Efficacy of fermentable 
carbohydrate restriction in 
IBS has been proven by 
several researchers, who also 
found significant changes in 
gut microbiota.
El-Salhy 
et al52
2014 FODMAPs seem responsible 
for endocrine activity 
from specialized GI cells, 
increasing GI motility and 
sensation and triggering IBS 
symptoms.
Mullin and 
Shepherd56
2014 Diet in the management of 
IBS has become increasingly 
important in recent years, 
with several studies trying 
to validate the relationship 
between certain foods 
(FODMAPs) and symptom 
onset.
FODMAPs, fermentable oligo-, di-, and monosaccharides and polyols; 
GI, gastrointestinal; IBS, irritable bowel syndrome. 
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some degree of lactase activity.76 Common foods rich in lac-
tose are milk, yogurt, ice cream, custard, and soft cheeses.72
FODMAP oligosaccharides are fructans (linear or branched 
fructose polymers with a glucose terminal end and a chain 
length, or degree of polymerization, less than 10, the naturally 
occurring storage carbohydrates of a variety of vegetables) and 
galactans, whose digestion and absorption are impossible for 
humans because they do not have enzymes to break them 
down.77–79 Thus, they are not absorbed in the small intestine 
and are rapidly fermented, causing gas formation.77 Fructans 
can be found in several foods belonging to the large families of 
fruits, cereals, legumes, nuts, and vegetables such as peach, 
persimmon, watermelon (among fruits), artichokes, beetroot, 
Brussels sprouts, chicory, fennel, garlic, leek, onion, peas 
(among vegetables), wheat, rye, barley (among grains and 
cereals), pistachios (among nuts and seeds), lentils, chickpeas 
(among legumes), and chicory drinks.77,78 Wheat is a major 
source of fructans in the diet, containing 1%–4% fructans in 
solid matter.77 It is the main constituent of bread, pasta, break-
fast cereals, cakes, cookies, and crackers. Rye also contains 
fructans, whose chain length is longer than that found in wheat, 
the one thing that could make them less osmotically active or 
as rapidly fermented.77–81 An additional source of fructans is 
inulin (a long-chain fructan, with a chain length or degree of 
polymerization greater than 10), which is increasingly being 
added to foods for its putative probiotic effects.82–85 The main 
GOS dietary forms are raffinose, which is composed of 1 mol-
ecule of fructose, 1 glucose, 1 galactose, and 1 stachyose, 
whose composition is the same as raffinose except for 1 more 
galactose molecule.79 Raffinose and stachyose cannot be bro-
ken down to their simple sugar constituents because humans 
lack the enzyme α-galactosidase that hydrolyzes the galacto-
sidic linkages.86 The primary dietary sources of galactans are 
certain legumes, such as baked beans, red kidney beans, chick-
peas, lentils, and soy products, but can also be found in green 
and yellow (wax) beans, Brussels sprouts, and cabbage.86,87 
Large amounts of galactans due to increased consumption of 
legumes, commonly used as important alternative sources of 
protein in specific diets, are often consumed by vegetarians, 
particularly those following vegan diets. Other cuisines that 
are based on these foods, such as the Indian (many curries and 
soups) and Mexican (“chili con carne” and refried beans), are 
likely to provide greater intake of galactans.77–79,86,87
Polyols (ie, sorbitol, mannitol, maltitol, xylitol, erythritol, 
polydextrose, and isomalt) are sugar alcohols.88 They appear to 
have primary roles in plants as energy reserves and agents of 
osmolarity, but recently they have been used as sugar substi-
tutes by the food industry to produce low-calorie food prod-
ucts.88,89 Only about one-third of what is consumed is actually 
absorbed, and the proportion varies depending on different 
polyols and individuals. Polyols are probably slowly absorbed 
by passive diffusion: a system of active transport in the small 
intestine epithelial barrier has not been demonstrated.89 The rate 
of absorption is related to 3 factors. First, the diffusion depends 
on molecular size, occurring through “pores” in the epithelium. 
Second, there is variation of pore size along the small intestine, 
with larger pores proximally. Finally, pore size is affected by 
mucosal disease (eg, pore size decreases in celiac disease).89 So 
it is not surprising that studies on the absorption of some poly-
ols, such as sorbitol and mannitol, have highlighted consider-
able individual variation and a fermentation extent strictly 
dependent on intake amount.88,89 Sorbitol tends to be more com-
mon in fruits, whereas mannitol is found more commonly in 
vegetables. Common foods in this group are apples, apricots, 
avocado, blackberries, cherries, nectarines, pears, plums, prunes 
(among fruits), cauliflower, mushrooms, and snow peas (among 
vegetables). As aforesaid, polyols are also used as artificial 
sweeteners, being identified by the following additive numbers 
on food packages: E420 (sorbitol), E421 (mannitol), E965 
(maltitol), E967 (xylitol), and E953 (isomalt). Finally, sorbitol 
is often found in foods rich in free fructose and has been mar-
keted as a laxative; this latter feature has made a warning neces-
sary on the boxes of candy, whenever used as a sweetener, 
especially in sugarless chewing gum.66,88,89
Obviously, differences in dietary habits make the relative 
consumption of different FODMAP subgroups vary across eth-
nic and dietary groups. In North American and Western 
European diets, fructose and fructans are by far the most wide-
spread in the diet and therefore the ones to which nearly all 
patients with IBS are exposed in their everyday diet (Table 3).
Benefits of a Low FODMAP Diet for 
Patients With IBS
FODMAP-restricted diets have been used for a long time, with 
varying success, in the management of patients with functional 
gut symptoms and IBS. The best examples are restriction of 
fructose, with or without sorbitol, and lactose.‡ However, the 
very limited success of this approach is the most likely reason 
why this kind of diet has not been widely used. A limited 
restriction of FODMAPs ignores the likelihood that there is a 
potentially large amount of FODMAPs in the everyday diet, 
each of which has similar end effects in the bowel.28,90 The 
innovation in the so-called FODMAP concept or approach is 
that a global restriction should have a far greater and more con-
sistent effect than a limited one.28 Thus, the central focus 
should be to reduce the intake of all poorly absorbed short-
chain carbohydrates, rather than merely concentrating on one 
of these, to be more effective in preventing luminal distension. 
Such a global approach should optimize symptom control in 
patients with IBS, reducing carbohydrates that have similar 
actions (high osmotic power and rapid fermentation).28
Shepherd et al44 were the first to confirm the role of a low 
FODMAP diet in managing GI complaints by means of a 
research trial designed as a retrospective evaluation of patients 
with IBS and fructose malabsorption on a low-fructose/fructan 
diet (and polyols, if the patients noted symptom induction), 
balancing fructose (but not fructans) with glucose 
‡References 18–21, 25, 30, 33, 34, 36, 38–40, 43–45, 49, 51.
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by supplementing foods with excess free fructose with free 
glucose. Abdominal symptom improvement on this dietary 
regimen was reported by 74% of patients. Efficacy was durable 
and closely related to dietary compliance (ie, better in those 
compliant than noncompliant). However, the main weakness 
of the study was that it was a retrospective analysis; it is uni-
versally known that a retrospective analysis of diet experience 
is not the ideal way to determine whether efficacy was due to a 
placebo effect, which is notoriously high in clinical trials of 
patients with IBS.44 Efficacy of the diet was confirmed by a 
randomized, double-blind, placebo-controlled, quadruple-arm 
crossover, rechallenge trial with fructose, fructans, fructose 
plus fructans, and glucose (as placebo), at varying doses (low, 
medium, or high), in 25 patients with IBS, as defined by the 
Rome II criteria: all patients should have documented fructose 
malabsorption (positive fructose hydrogen breath test follow-
ing a 35-g fructose load) as well as a previously demonstrated 
durable symptomatic response (3–36 months) to reduction of 
dietary FODMAPs. Abdominal symptoms, such as pain, bloat-
ing, and flatulence, recurred in a dose-dependent way in 70%–
80% of patients when fed with pure forms of FODMAPs, 
especially with fructose plus fructans; this proved to have an 
additive effect, especially compared with 15% reporting the 
same abdominal symptoms with a similar diet spiked with pla-
cebo (glucose).9 A possible weakness of the above-reported 
studies is the origin: they have all been carried out by a single 
center in Australia. This specific feature has made a subsequent 
comparative study of this dietary approach necessary, which 
was performed in the United Kingdom and demonstrated the 
superiority of a low FODMAP diet compared with a dietary 
approach previously considered best practice (ie, National 
Institute for Health and Clinical Excellence diet). The low 
FODMAP intake group reported satisfaction with their symp-
tom response compared with the standard group. Symptom 
score data showed better overall symptom response in the low 
FODMAP group compared with the standard diet group. More 
specifically, the most significant improvements were achieved 
in bloating, abdominal pain, and flatulence.35,47 The same ben-
eficial effects of a low FODMAP diet have been confirmed by 
a more recent study, which included patients with IBS who 
underwent hydrogen/methane breath testing for fructose and 
lactose malabsorption and had received dietary advice regard-
ing the low FODMAP diet. Particular attention should be paid 
to the greater symptomatic improvement in those with fructose 
malabsorption compared with the others. An association 
between fructose malabsorption and better efficacy of the diet 
Table 3. Main FODMAPs and Their Alimentary Origin.
Food Component Dietary Form Foods
Monosaccharide Fructose Fruits: apples, pears, nashi pears, clingstone peaches, mango, sugar snap peas, 
watermelon, cherries, tinned fruit in natural juice
 Honey
 Vegetables: asparagus, artichokes, sugar snap peas
 Sweeteners: fructose, high-fructose corn syrup
 Large total fructose dose: concentrated fruit sources; large servings of fruit, 
dried fruit, fruit juice
Disaccharides Lactose Milk: cow, goat, and sheep (regular and low fat)
 Ice cream
 Custards
 Yogurt (regular and low fat)
 Cheeses: soft and fresh (eg ricotta, cottage)
Oligosaccharides Fructans and/or galactans Fruits: watermelon, custard apple, white peaches, rambutan, persimmon
 Vegetables: artichokes, asparagus, beetroot, Brussels sprouts, broccoli, cabbage, 
fennel, garlic, leeks, okra, onions, peas, shallots
 Cereals: wheat and rye when eaten in large amounts (eg, bread, pasta, couscous, 
crackers, biscuits), barley
 Nuts and seeds: pistachios
 Legumes: chickpeas, lentils, red kidney beans, baked beans
 Inulin
Polyols Sorbitol, mannitol, 
maltitol, xylitol, 
erythritol, polydextrose, 
and isomalt
Fruits: apples, apricots, cherries, lychee, nashi pears, nectarines, pears, peaches, 
plums, prunes, watermelon
 Vegetables: avocado, cauliflower, mushrooms, snow peas
 Sweeteners: sorbitol (E420), mannitol (E421), xylitol (E967), maltitol (E965), 
isomalt (E953), and others ending in -ol
 Laxative
Data from Gibson and Shepherd.71,72,90 FODMAPs, fermentable oligo-, di-, and monosaccharides and polyols.
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may reflect large amounts of fructose in the diet of these 
patients.24 Finally, in an Australian study in 2014, a group of 
patients with IBS and healthy individuals (controls matched 
for demographics and diet) were randomly assigned to groups 
that received 21 days of either a diet low in FODMAPs or a 
typical Australian diet, followed by a washout period of at least 
21 days, before crossing over to the alternate diet. In this con-
trolled crossover study, the patients with IBS effectively 
reduced functional GI symptoms when consuming a diet low 
in FODMAPs.32
However, there is no evidence that fructose and/or lactose 
malabsorption and/or FODMAP consumption is more frequent 
in patients with functional bowel symptoms (including IBS) 
than in those without such factors. In other words, FODMAPs 
cannot be considered the cause of functional bowel disorders 
but rather represent a dietary trigger and an opportunity for 
treatment.19
Table of FODMAP Content of Foods: 
Strengths and Weaknesses
Thanks to the above-mentioned studies, it was possible to gain 
better and more specific knowledge about food composition to 
fine-tune the FODMAP approach.90 This included the consid-
eration of a broader range of FODMAPs, including FOS, GOS, 
and mannitol, in addition to fructose, lactose, and sorbitol. 
Today, a low FODMAP diet avoids these 6 carbohydrates, with 
published tables of food composition available for fruits, veg-
etables, breads, and cereals.91–93 Great importance should also 
be given to the possibility of simply and accurately assessing 
FODMAP consumption in individuals and specific popula-
tions, such as disease groups. Recently, Halmos et al54 calcu-
lated that the mean FODMAP content of an Australian mixed 
diet is 23.7 g/d, ranging from 16.9–30.6 g/d.
The impact that dietary modification of FODMAPs can 
have on functional gut symptoms and the putative role that 
FODMAPs might play in the pathogenesis of specific GI dis-
eases have been highlighted.24,25 In this regard, administration 
of food frequency questionnaires (FFQ) is the method of 
choice. Broad food composition in an Australian population 
has been studied using the Monash University Comprehensive 
Nutrition Assessment Questionnaire (CNAQ), a 297-item 
comprehensive, semiquantitative FFQ, to estimate consump-
tion of macro- and micronutrients, FODMAPs, and glycemic 
index/load.94 This FFQ has been validated by comparing FFQ 
responses on 2 occasions, plus four 1-week semiquantitative 
food records kept during a 12-month period, in a broad range 
of participants, and the data were analyzed using 4 statistical 
methods. The CNAQ will probably be a useful tool for future 
investigation of FODMAPs and other dietary components in 
chronic disease and GI disorders.94
Even though several studies have demonstrated the efficacy 
of a low FODMAP diet in treating IBS symptoms, there are 
many limitations in developing tables of FODMAP-rich and 
FODMAP-poor foods.93–95 To date, only a limited description 
of FODMAP content can be found in published lists of food 
composition. This limitation has been only partially overcome 
by the development of methods to measure FODMAP content, 
together with a systematic examination of fruits, vegetables, 
and cereals.93 However, the biggest limitation is in the absence 
of a unique and widely approved cutoff level of FODMAP con-
tent, which should dictate whether a food must be classified as 
“high” FODMAP content or not. This is further complicated by 
the fact that the total FODMAPs ingested, rather than just the 
consumption of a single food containing FODMAPs in any one 
meal, is a major factor in determining whether symptoms will 
be induced. In the original description of the diet, only careful 
clinical observation (obtaining feedback from patients regard-
ing foods that they identified as triggers for symptoms) allowed 
the identification of cutoff values.92–94 The reported foods were 
examined for trends in the pooled food composition table. For 
example, foods and beverages containing >0.5 g fructose in 
excess of glucose per 100 g, >3 g fructose in an average serving 
quantity regardless of glucose intake, and >0.2 g fructans per 
serving were considered at risk of inducing symptoms.44,92,93,95
Therefore, according to this first study, the total dose indi-
cated for therapeutic benefit in the IBS population is less than 
0.5 g FODMAPs per sitting or less than 3 g FODMAPs per 
day. These values are considerably lower than the amount 
obtainable through the diet, as suggested in a validated FFQ of 
an average Australian diet.44,94
Possible Mechanisms of FODMAP 
Triggering of IBS Symptoms
The mechanisms by which FODMAPs produce effects have 
been studied in 2 separate trials. Using an ileostomy model, it 
was confirmed that FODMAPs consumed in meals are poorly 
absorbed in the small intestine.13 Interestingly, an osmotic effect 
of the carbohydrates has been suggested by the increased water 
content of the output from the stoma. This may well be the 
physiologic mechanism inducing diarrhea in some individu-
als.13 In this context (ie, osmotic effect of FODMAPs), mag-
netic resonance imaging analysis allowed studying the small 
bowel water content (SBWC). It was higher after a meal con-
taining mannitol, but not a glucose meal, in patients with IBS 
with diarrhea but not in healthy volunteers.96 The second 
research line was a single-blind, crossover, short-term, inter-
ventional study, aimed to assess breath hydrogen during low 
and high FODMAP diets in healthy volunteers and in patients 
with IBS. Higher levels of breath hydrogen were produced with 
the high FODMAP diet both in healthy volunteers and in 
patients with IBS, who proved to have higher levels during each 
dietary period than the controls.37 GI symptoms (abdominal 
pain, bloating, wind, heartburn, and nausea) and lethargy were 
significantly and quickly induced by the high FODMAP diet in 
patients with IBS, while only increased flatus production was 
reported by healthy volunteers. Conversely, breath hydrogen 
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production was reduced both in healthy volunteers and in 
patients with IBS when consuming a low FODMAP diet, with 
consequential reduction in GI symptom scores in the IBS popu-
lation.37 This confirms the additive bacterial fermentative nature 
(with production of short-chain fatty acids, including butyrate, 
and gases such as carbon dioxide and hydrogen) of the short-
chain carbohydrates and their role in the induction of bloating, 
abdominal distension and pain, and excessive flatus.37 In this 
different context (bacterial fermentation), Brighenti et al97 
showed that hydrogen production speed is inversely propor-
tional to FODMAP chain length. Just a few years later, a study 
analyzing activity of the short-chain carbohydrates after enter-
ing the colon indicated that the fermentative rather than osmotic 
effects predominated in most people.23
Other studies by Piche et al98,99 point out how FODMAPs 
might also generate IBS symptoms through motility effects (ie, 
acceleration of small intestinal and colon transit and increase 
in gastroesophageal reflux). These effects could be connected 
to the already described osmotic effect of FODMAPs and an 
activation of neural feedback pathways and/or hormonal 
changes from short-chain fatty acid production at the same 
time, secondary to FODMAP bacterial fermentation. In this 
context, several GI endocrine cell abnormalities have been 
reported in patients with IBS in response to luminal stimuli 
(mostly ingested nutrients). Specialized cells release hormones 
into the lamina propria, where they exert paracrine/endocrine 
activity. FODMAPs seem responsible for such endocrine 
responses, increasing GI motility and sensation, thereby trig-
gering IBS symptoms.52
Furthermore, an injury of the colon epithelium and increased 
intestinal permeability have been shown in animal models, 
including rats fed with fructo-oligosaccharides. These rats also 
developed more severe colitis when infected with Salmonella 
species.100 This finding may be particularly relevant given the 
evidence that 7%–30% of patients with acute gastroenteritis 
subsequently develop postinfection IBS.101
FODMAPs may also be responsible for systemic effects, 
such as mild depression with fructose and lactose malabsorp-
tion in women with IBS.102 This depression seems to improve 
when free fructose is eliminated from the diet.34 A possible 
pathogenic mechanism could be identified in the lower levels 
of circulating tryptophan, suggesting secondary deficiency in 
serotonin synthesis, in patients with fructose malabsorption on 
an unrestricted diet.103
The pathogenic role of FODMAPs in IBS symptoms is 
probably also associated with the intestinal flora of these 
patients.104–106 Bacteria, such as Clostridium species, break 
down FODMAPs with gas production, thus causing large 
intestine distension, with abdominal discomfort or pain.104 
Patients with IBS have fewer Lactobacillus and Bifidobacterium 
species in their intestinal flora than do healthy individuals. 
These bacteria have been shown to bind to epithelial cells, 
inhibiting pathogen adhesion and, at the same time, enhancing 
barrier function.104–106 Furthermore, these bacteria species do 
not produce gas upon fermenting carbohydrates, an effect that 
is amplified as they also inhibit Clostridium species growth. 
Increased tolerance to FODMAPs could be achieved by replac-
ing the intestinal flora with these beneficial bacteria.104–106
Finally, it is of some importance to note that FODMAPs are 
commonly added to enteral formula, in the form of FOS and 
inulin.107,108 Enteral nutrition (EN) is frequently used as the 
main source of nutrition in hospitalized patients, so it is reason-
able to hypothesize that EN provides more FODMAPs than 
usual dietary consumption in these latter patients, increasing the 
risk of diarrhea, one of the most common complications of 
EN.108 Halmos et al54,108 were the first to assess this hypothesis 
through a retrospective study investigating all possible predic-
tors of diarrhea in hospitalized patients, with a particular focus 
on 7 enteral formulas, whose FODMAP contents ranged from 
10.6–36.5 g/d vs the reported 16.9–30.6 g/d of a mixed 
Australian diet (both values well in excess of the suggested 3 
g/d reported for low FODMAP diets).47 Any variables that 
could possibly contribute to diarrhea were analyzed, and spe-
cific data were collected.107,108 Inpatients with a longer length of 
stay and receiving EN for a longer period were positively asso-
ciated with development of diarrhea. All the enteral formulas, 
excluding Isosource 1.5 (Nestlé Health Science, Lutry, 
Switzerland), were positively related to diarrhea onset. Analysis 
of the specific composition of Isosource 1.5 proved the 
FODMAP content (just 10.6 g/d) was the only significant dif-
ference: 30%–53% lower than all the other formulas.107 These 
data were obtained through methods previously validated for 
food analysis—that is, high-performance liquid chromatogra-
phy (HPLC) and enzymatic assays.92,93 Recently, in another ret-
rospective study, the same author assessed Isosource 1.5, which 
had a protective effect against developing diarrhea. However, 
the FODMAP content of commercial enteral formulas is not 
shown in product information, and a prospective randomized 
study is needed to test the role of FODMAPs in EN-associated 
diarrhoea.108
All of these insights are consistent with current understand-
ing of the pathophysiological mechanisms that underlie IBS. 
Among these, visceral hypersensitivity is the most important; 
distension of the gut due to increased gas production and other 
mechanisms abnormally stimulates the enteric nervous system, 
which reacts by altering its motility patterns and sending mes-
sages to the brain that may be interpreted as bloating, discom-
fort, and pain.108–111 Dietary components that putatively lead to 
luminal distension in the regions of interest have the following 
characteristics: (1) poorly absorbed in the proximal small 
intestine; (2) formed by small molecules (ie, osmotically 
active); (3) rapidly fermented by bacteria, potentially fer-
mented by small intestinal and cecal bacteria, expanding the 
bacterial population at the same time (ie, a “probiotic” effect); 
and (4) associated with hydrogen production.109–112 Dietary 
FODMAPs are the best fit for these mechanisms. In others 
words, to better highlight the concept, FODMAPs do not cause 
IBS but are the possible trigger for symptom onset and 
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represent an opportunity to reduce the patient’s symptoms.111 
All of this steers us away from the more traditional concepts of 
fructose and lactose “intolerance” vs fructose and lactose 
“malabsorption.” Concisely, visceral hypersensitivity is the 
main cause of a disproportionate reaction, mediated by the 
intestinal nervous system, to the ingestion of carbohydrates 
such as fructose and lactose and therefore not bound to any 
phenomenon of malabsorption. Delivery of dietary FODMAPs 
to the large intestine is a normal phenomenon, which will not 
cause any disproportioned reaction without the underlying 
presence of visceral hypersensitivity.109,111 Therefore, a low 
FODMAP diet reduces osmotic effects, fermentation, and 
associated gas production and is likely to minimize the disten-
sion induced by food, thereby reducing symptom severity.111,112 
Alterations in the number, composition, function, and location 
of the microbiota could represent other factors concurring to 
pathogenesis of IBS symptoms.104–106 It has been shown that 
some patients with IBS may have small intestinal bacterial 
overgrowth (SIBO). Such a condition could cause increased 
permeability in the small intestine and fermentation of malab-
sorbed carbohydrates in the narrow lumen of the small intes-
tine, subsequently inducing abdominal pain and discomfort. 
These patients may have more predominant methane-produc-
ing bacteria that, when fermenting carbohydrates, delay intes-
tinal transit and cause constipation.109–112
Diagnosis of FODMAP “Malabsorption”
To date, diagnosis of food intolerance in most areas is still 
unfortunately impossible. A reliable measure of test sugar 
absorption can be provided by assessment of breath hydrogen 
levels.113 A significant rise in breath hydrogen following test 
sugar intake demonstrates poor absorption with subsequent 
fermentation by intestinal microflora. In patients with IBS, a 
positive breath test could allow the identification of carbohy-
drates causing symptom onset and whose exclusion from the 
diet could reduce intestinal discomfort. Contrariwise, a nega-
tive breath test proves the complete absorption of the sugar, 
suggesting that the patient can continue to consume this sugar 
without affecting his or symptoms.113 Therefore, breath hydro-
gen testing to determine absorption of a fructose and/or lactose 
load is very useful since it can reduce the necessary restriction 
of diet. Lactose intolerance can also be detected both by a lac-
tose tolerance test, measuring the amount of blood glucose 
after oral lactose consumption, and by detection of lactase 
activity through small bowel (duodenal) biopsy.113 Breath 
hydrogen testing is not strictly necessary for the diagnosis of 
food intolerance; the fully restricted diet can be initiated, but 
altering the diet entails a risk of nutrition compromise, and in 
general it is a good principle not to restrict foods if not neces-
sary.113,114 The breath tests that allow detection of FODMAP 
malabsorption are routinely conducted with fructose (testing 
dose of 35 g), lactose (testing dose of 25–50 g), and sorbitol 
(testing dose of 10 g). Nevertheless, careful physicians should 
remember that 3 other FODMAPs need to be considered as 
potential triggers for IBS symptoms. A specific breath test for 
fructans and galactans is not available, since they are always 
malabsorbed and fermented.113,114 Furthermore, the mannitol 
breath test is rarely offered since it is not a widespread compo-
nent in the diet and can be investigated as a trigger through 
simple dietary elimination and rechallenge.113
Even if the use of breath tests to identify intolerance to 
FODMAPs could be useful, physicians should be aware of 
false positives. For example, it has been demonstrated that in 
patients with IBS with SIBO, diagnosed by lactulose breath 
test, a reliable and noninvasive test for the diagnosis of this 
condition (even if several recent studies suggest that the test 
can be flawed in diagnosing it), sugar breath tests (fructose, 
lactose, and sorbitol hydrogen breath tests), may be falsely 
abnormal. SIBO eradication with a 1-week course of antibiot-
ics normalizes sugar breath tests in most patients.114 These 
results suggest that in the presence of SIBO, sugars could be 
nonspecifically fermented by the large amount of intestinal 
bacteria, causing abnormal hydrogen production and conse-
quently a mistaken diagnosis of FODMAP intolerance.114 An 
alternative hypothesis to explain the false positives of the test 
could be damage of the small bowel mucosa, caused by bacte-
rial overgrowth, inducing a transient enzymatic or carrier pro-
tein deficiency and then multiple sugar malabsorption. 
Appropriate antibiotic therapy to eradicate the SIBO allows 
mucosa regeneration and healing, reverting to a negative breath 
test. Therefore, testing for SIBO should be performed before 
other sugar breath tests to avoid a misdiagnosis of sugar 
malabsorption.114
Practical Low FODMAP Diet 
Management
FODMAP Tolerance Assessment
The efficacy of the low FODMAP diet suggests that if dietetic 
expertise is available, it should be the first-line treatment. 
Since response to diet is variable and some patients could have 
a food allergy as well, it is important for physicians to better 
target a low FODMAP diet, identifying the predictors of both 
conditions. Symptoms may provide some hints: atopic history; 
symptoms referable to mast cell activation, such as flushing 
and tingling in the mouth; or concurrent systemic manifesta-
tions, such as urticaria or asthma, should direct considerations 
to food allergy.115 However, it has been suggested that the clas-
sic symptoms of IBS (bloating and frequent lower abdominal 
pain relieved by defecation) could also be due to a non–IgE-
mediated food allergy.116,117
By definition, FODMAPs are different carbohydrates char-
acterized by some identical features; considering their different 
nature, it is not surprising that not all FODMAPs will be symp-
tom triggers for all patients. Only those that are malabsorbed 
are likely to play a role. It is important to keep in mind that 
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fructans and galactans are always malabsorbed and fermented 
by intestinal microflora.42,118,119 So, if in healthy people, the 
result of consumption of these sugars is gas production and 
flatulence, then in patients with IBS, in whom conditions such 
as altered gut flora, visceral hypersensitivity, and motility dis-
orders are present, they could induce symptom onset.37 The 
remaining FODMAPs will induce symptoms only in the pro-
portion of patients with IBS that malabsorbs them. In this 
regard, the prevalence of fructose and lactose malabsorption in 
white patients with IBS is 45% and 25%, respectively.19 The 
sugar polyols, sorbitol and mannitol, are incompletely 
absorbed, but their low amounts found naturally in foods as 
well as in sugar-free products and medications are usually well 
absorbed in most people.19,25,120 Several differences between 
healthy individuals and those with IBS in small intestinal han-
dling of sorbitol and mannitol have been found in a random-
ized, double-blind, placebo-controlled crossover study.50 
Patients with IBS not only seem to absorb twice as much of 
these polyols, but they seem to do it more quickly for mannitol 
than for sorbitol compared with healthy individuals, who, in 
contrast, do not seem to present any difference in absorption 
rate between mannitol and sorbitol. Several hypotheses have 
been proposed to identify the cause of such differences, but 
further studies are required. One possibility is slower orocecal 
transit in patients with IBS. A lengthening of time of transit 
allows greater absorption of molecules that are passively and 
slowly absorbed.50 Alternatively, the differences in absorption 
patterns between healthy individuals and patients with IBS 
might reflect epithelial abnormalities, which have been 
reported in some subgroups of patients with IBS. Despite supe-
rior absorption, both sorbitol and mannitol induce specifically 
abdominal symptoms, suggesting that some mechanism(s) 
other than (or in addition to) their fermentation are involved. 
Fluid distension of the small intestine has been proposed 
because of the osmotic effect induced by slowly absorbed 
polyols in most of the small intestine.50 Such observations sug-
gest that polyol dietary restriction should be included in low 
FODMAP diets for patients with IBS, irrespective of their abil-
ity to absorb them according to breath hydrogen results. 
Therefore, in this context, breath testing to assess polyol 
absorption, as is frequently performed for fructose and lactose, 
may not be clinically useful or relevant.50,121 Even though 
breath tests are useful diagnostic tools helping physicians to 
implement specific and personalized low FODMAP diets, 
they cannot be considered mandatory, and the exclusion of 
polyols may still be appropriate in these patients.113,121 If 
breath testing cannot be performed, a trial of a complete low 
FODMAP diet can be conducted, followed by a rechallenge of 
any of the potentially well-absorbed carbohydrates (fructose, 
lactose, sorbitol, and mannitol).121 Tolerance to fructans and 
galactans can then be tested. In large amounts, these carbohy-
drates will always contribute to gas-associated symptoms, a 
phenomenon that can be observed even in healthy individuals 
for extreme amounts. However, small amounts of fructans and 
galactans may be tested to assess the level of tolerance in 
patients with IBS.37
Approach to Patients With Suspected 
FODMAP Intolerance
Nowadays, low FODMAP diets have been evaluated only as a 
dietitian-guided diet. This has mostly been achieved in a one-
to-one setting, together with the use of written educational 
material (information sheets or detailed publications) and rec-
ipe books, but group education sessions have also been used 
with apparent success.122 No data are available about the effi-
cacy of using instructions and diet sheets by patients them-
selves. However, physicians should be cautious in undertaking 
such an approach, due to the lack of sufficient ad hoc studies. 
The strategy that should be used consists of 2 different phases: 
(1) preliminary consultation and start of a low FODMAP diet 
and (2) challenge by FODMAP reintroduction.56 The first 
phase could be performed by physicians assisted by expert 
dietitians according to the following key points:
•• Define qualitatively and quantitatively the patient’s 
typical eating practices and lifestyle. This first evalua-
tion is important to identify the FODMAPs to which the 
patient has daily exposure. Useful methods to obtain 
such information are precompleted food recording dia-
ries (compiled for at least a 7-day period) and direct 
questioning during the consultation.
•• Explain the scientific basis of FODMAP malabsorption 
and subsequent fermentation to the patient. This step is 
of great importance to provide a basis for better under-
standing of food choice and increase the likelihood of 
compliance.
•• Provide specific dietary instructions (Table 4).
•• Discuss techniques to handle situations where food 
preparation cannot be controlled, such as eating away 
from home (eg, restaurants, school camps, and eating 
at friends’ homes).
•• Trial diet. To ensure symptoms are well controlled, a 
strict trial of the low FODMAP diet should be per-
formed for the first 6–8 weeks.
Assessment of symptom response under a strict FODMAP diet 
will subsequently lead to discussions of individual tolerance. 
Reintroduction of single carbohydrates, hence testing toler-
ance, is a vital stage of the dietetic process to ensure maximum 
variety in the diet, to avoid overrestriction and reduce a risk of 
nutrition inadequacy due to long-term diets.56 Rechallenge 
includes consumption of, for example, fructose (2 tsp honey), 
lactose (125–250 mL milk or 200 g yogurt), fructans (2 slices 
wheat bread or 1 clove of garlic), galactans (1/2 cup lentils or 
legumes), sorbitol (4 dried apricot halves), and mannitol (1/2 
cup mushrooms). Whenever response to the diet is inadequate, 
specific questioning is required to determine compliance to the 
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diet, modifying any deficiency. If compliance is established, 
attention should be paid to reducing resistant starch and both 
insoluble and soluble fiber intake. Physicians should always 
consider other possible triggers such as gluten and/or food 
chemicals, as well as other factors influencing GI system activ-
ity such as caffeine, fat, meal size, and regularity.72
Low FODMAP Diet Compliance
Patient compliance with a low FODMAP diet, if correctly 
introduced, is remarkably good. Shepherd et al44 found compli-
ance (complete or nearly so) with the diet in about 75% of 
patients by retrospective review. The study analyzed patients 
with proven fructose malabsorption and symptoms of IBS who 
had been instructed about fructose malabsorption after a 
median of 14 months (range, 2–40 months) of dietary interven-
tion, paying particular attention to diet compliance, difficulties 
in consuming a correct diet, and strategies used by patients to 
avoid contamination. The main barriers to compliance included 
an unwillingness to undertake dietary recommendations, diffi-
culties accessing (and increased expense) of wheat-free spe-
cialty foods, and dislike of the taste of these foods. Another 
possible cause, particularly important in modern society, is the 
necessity of eating out due to work and social concerns. Finally, 
most patients implemented the dietary strategies by self-select-
ing alternative foods.24,44
Gearry et al122 found a particularly good response to the diet 
in a population of patients with inflammatory bowel disease 
and functional gut symptoms, with higher education status, 
working no more than 35 hours per week and using appropriate 
cookbooks, suggesting that the diet does require effort and 
time commitments.
Low FODMAP Diet in Patients With IBS: 
Limitations and Potential Concerns
Despite all the potential of low FODMAP diets, they are far 
from being a panacea for patients with IBS. Surely, they 
provide good relief of symptoms in many patients (ie, those 
with bloating and diarrhea), but it is of little relevance in some 
others.47 Further studies are required to identify predictive fac-
tors of benefit apart from dietary compliance.44 Since the diet 
does not influence the pathophysiologic substrate of IBS, inter-
mittent symptoms remain in many patients, albeit at a now tol-
erable level. Symptomatic hyperresponsiveness to the 
reintroduction of FODMAPs in the diet has recently been 
described,32 but no specific mechanism has been clearly identi-
fied to date. Experimental data showed that in rats fed fructose-
poor diets, GLUT-5 expression falls, as does the ability to 
absorb fructose from the small intestine.123 Whether or not this 
occurs in humans and contributes to IBS symptoms, fructose 
reintroduction in the diet warrants further investigation.123,124
A feature of greater importance, requiring further and better 
definition, is the safety of long-term low FODMAP diets. 
Restrictive diets are at risk of being nutritionally inadequate 
and potentially expensive. In general, by the very definition of 
a low FODMAP diet, it should not compromise nutrition ade-
quacy (ie, it should not eliminate whole categories of foods, as 
is the case for several other types of diet). Foods are substituted 
with a suitable alternative within the same food group. The 
greatest difficulties are found with legumes (including chick-
peas, baked beans, red kidney beans, and lentils), since these 
all contain fructans and galactans.92,93 Fortunately, people on a 
low FODMAP diet can still enjoy tofu, and foods such as 
seeds, nuts, and quinoa are encouraged, as well as eating 
legumes in small amounts.72 Reduction in fiber intake might be 
a consequence of the restriction of wheat-based products, but 
physicians should opportunely advise the patients as part of 
dietary counseling to ensure continuing adequate intake of 
resistant starch and nonstarch polysaccharides.125 A possible 
detrimental effect of an elimination diet, although character-
ized by a wide variety of foods, such as a low FODMAP diet, 
is nevertheless present, because patients greatly reduce the 
intake of fiber and eliminate some carbohydrates, such as inu-
lin, characterized by probiotic effects (ie, induction of selective 
bacterial proliferation, especially bifid bacteria).124–126 For 
Table 4. Suggestions for Correct Management of FODMAP Intake.
Dietary Advice Note(s)
Reduce dietary fructose load, especially in the form of free 
fructose.
Unless complete fructose absorption has been demonstrated by 
breath hydrogen testing.
Encourage food intake characterized by fructose/glucose 
balance or where glucose is in excess of fructose.
Advise coingestion of free glucose to “balance” excess of free 
fructose problematic foods.
Avoid foods that contain significant free fructose in excess of 
glucose.
Restrict lactose-containing foods. Whenever lactose malabsorption is demonstrated on breath 
hydrogen or lactose tolerance testing.
Avoid foods that are a substantial source of fructans and 
galactans.
Diets where it is possible to find the highest levels of fructans 
and galactans are vegan, Indian, and Mexican cuisines.
Avoid polyols. Advise the patients about their role as sweeteners in several 
foods, chewing gums, drinks, and so on.
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example, possible interactions between the diet and luminal 
indices associated with colorectal carcinogenesis require eluci-
dation.95,118,126,127 For all these reasons, a strict, long-term, low 
FODMAP diet is not recommended. Rather, after achieving 
good symptomatic response, a reintroduction of FODMAP 
foods should be instituted as soon as possible to find the level 
of food restriction that the individual requires to adequately 
control symptoms without encountering nutrition imbalance. A 
low FODMAP diet is also not recommend for healthy people 
because of concerns regarding changes in luminal microflora 
and fiber intake.70
FODMAPs and Wheat Sensitivity
In recent years, increasing interest has surrounded the condi-
tion named “nonceliac gluten sensitivity.”128 Patients with 
NCGS show IBS-like symptoms, often associated with extrain-
testinal manifestations, which disappear on a gluten-free diet. 
However, it is not known which components of wheat cause 
the symptoms in patients with NCGS, and because there is no 
definite proof that gluten is really the culprit, we suggested the 
term nonceliac wheat sensitivity (NCWS).129 Obviously, the 
first diagnostic approach for these patients must be to exclude 
a celiac disease diagnosis. Consequently, to match the criteria 
for NCGS, these patients must be negative for celiac disease 
(CD) serology (anti–endomysial antibodies and/or anti–tissue 
transglutaminase IgA and IgG) and must have a normal duode-
nal histopathology. Furthermore, these patients must have neg-
ative immune allergy tests to wheat since wheat allergy also 
must be excluded. These individuals show clinical symptoms 
that can overlap with CD symptoms and show a resolution of 
symptoms when started on a gluten-free diet, implemented in a 
blinded fashion to avoid a possible placebo effect of the dietary 
intervention.128 Very recently, Biesiekierski et al,17 in a pla-
cebo-controlled, crossover rechallenge study, did not find any 
evidence of specific effects of gluten in patients with NCGS 
placed on diets low in FODMAPs. Consequently, the authors 
suggested that NCGS might not be a real entity and that it 
might be confounded by FODMAP restriction. Accordingly, 
they concluded that at least in their highly selected cohort, glu-
ten might not be a specific trigger of functional gut symptoms 
once dietary FODMAPs are reduced. This point of view con-
siders the toxic effect of gluten in patients with NCGS, previ-
ously demonstrated in several other studies and by these 
authors themselves, only as a contribution to the FODMAP 
dietary load.17 It should be said, however, that the patient popu-
lation included in the above study was highly selected. To be 
sure to exclude patients with celiac disease, the authors 
excluded all patients carrying the HLA-DQ2 or HLA-DQ8 
haplotype who have a simple duodenal lymphocytosis with 
normal villi/crypts ratio (Marsh 1 histology). In this way, they 
excluded more than 55% of the patients (82 of 149) initially 
recruited.17
Furthermore, previous studies had demonstrated that 
HLA-DQ2 and duodenal lymphocytosis are frequent find-
ings in patients with NCGS. A retrospective study of ours, 
which included the most numerous NCGS patient population 
published so far, showed that about 50% of patients with 
NCGS had the DQ2 haplotype and that a higher percentage 
showed duodenal lymphocytosis.16 Another study by 
Wahnschaffe et al130 demonstrated that HLA-DQ2 expres-
sion is a useful marker to identify a subgroup of patients with 
diarrhea IBS who are likely responders to a gluten-free diet. 
Furthermore, Vazquez-Roque et al131 provided a mechanistic 
explanation for the observation that gluten withdrawal may 
improve patient symptoms in IBS, showing also that biologi-
cal effects of gluten were associated with the HLA-DQ2 or 
HLA-DQ8 genotype. Thus, the exclusion of HLA-DQ2 
patients having normal villi at duodenal histology very prob-
ably does not permit studying a relevant percentage of 
patients with NCGS who have immunologic activation at the 
basis of their gluten-related symptoms. This probable role 
for an immune reaction in a percentage of patients with 
NCGS is suggested by mucosal studies132 and by the high 
levels of serum anti-gliadin IgG antibodies (the “old anti-
bodies” toward the native gliadin) found in NCGS, which 
fall on gluten-free diets.133
Finally, there are several elements supporting the hypothe-
sis that a percentage of patients with NCGSs have a pathogenic 
mechanism based on non-IgE food allergy, a condition that can 
cause duodenal lymphocytosis.15 On the other hand, the con-
cern to exclude a CD diagnosis by excluding from the study on 
NCGS the patients with IBS who have a duodenal lymphocy-
tosis is not justified, since no current guidelines consider CD 
diagnosis in patients with normal villi and negative CD-specific 
serum antibodies.15,133
The association between IBS, FODMAPs, and wheat sensi-
tivity has been recently stressed by Mullin et al.56 Their review 
of the dietary management of patients with IBS points out how 
wheat may provoke symptoms for several reasons: autoimmune 
disorder trigger, high fructans contents and member of the fam-
ily of highly fermentable FODMAPs, and high IgE-mediated 
and non–IgE-mediated allergenicity (among the top 8 food 
allergens).
In conclusion, regarding the role of FODMAPs in NCGS, 
we think that the literature data support the hypothesis that 
a low FODMAP diet can be useful in a percentage of these 
patients, probably those in whom a “biochemical-digestive 
mechanism” plays a prevalent role in causing the symptoms 
(Figure 2). However, as we have already suggested, we 
think that NCWS is a heterogeneous condition, which 
includes different subgroups of patients who have different 
pathogenic mechanisms: strong data suggest a direct patho-
genic role of wheat-cereal proteins (not only gluten) in a 
subgroup, probably the biggest subgroup of these 
patients.15,134
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Conclusion
There is emerging evidence for the role of food in triggering 
IBS symptoms (FODMAPs, IgE-mediated food allergies, and 
non-IgE food sensitivities and intolerances) and the relief pro-
vided by specific elimination diets. Changes in dietary intake, 
even if they do not represent a cure and do not influence the 
pathogenic mechanisms, allow improvement in symptoms and 
quality of life. To date, several studies highlight the role of low 
FODMAP diets, which improve symptoms in many patients 
with IBS. The increasing evidence supporting this dietary 
approach, as well as its relative ease of implementation, sup-
ports the hypothesis that a low FODMAP diet should be the 
first dietary approach in patients with IBS. However, many 
points remain to be clarified, including the evaluation of pos-
sibly significant nutrition concerns, especially in patients who 
do not have the help of a dietitian. Further studies are required 
to better identify those who can benefit from a low FODMAP 
diet and those in whom this diet should not be applied. 
Biomarkers to identify non–IgE-mediated food allergy and 
better methods to reveal problem food types are also required. 
Besides carbohydrates, there are many other food components 
worthy of study; among these, dietary fat has been shown to 
change visceral hypersensitivity, and naturally occurring 
chemicals widespread in foods can interact with receptors in 
the gut or have direct, possibly pharmacologic, actions on the 
enteric nervous system and mast cells.
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